MA54379B1 - Nouvelles formes cristallines d'un thienopyrimidine inhibiteur de mcl-1 - Google Patents

Nouvelles formes cristallines d'un thienopyrimidine inhibiteur de mcl-1

Info

Publication number
MA54379B1
MA54379B1 MA54379A MA54379A MA54379B1 MA 54379 B1 MA54379 B1 MA 54379B1 MA 54379 A MA54379 A MA 54379A MA 54379 A MA54379 A MA 54379A MA 54379 B1 MA54379 B1 MA 54379B1
Authority
MA
Morocco
Prior art keywords
crystalline forms
thienopyrimidine
mcl
inhibitor
new crystalline
Prior art date
Application number
MA54379A
Other languages
English (en)
French (fr)
Other versions
MA54379A (fr
Inventor
Michael Lynch
Baets Emilie De
Julien Auvray
Nicolas Leblanc
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of MA54379A publication Critical patent/MA54379A/fr
Publication of MA54379B1 publication Critical patent/MA54379B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA54379A 2018-12-06 2019-12-05 Nouvelles formes cristallines d'un thienopyrimidine inhibiteur de mcl-1 MA54379B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306634 2018-12-06
PCT/EP2019/083773 WO2020115183A1 (en) 2018-12-06 2019-12-05 New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them.

Publications (2)

Publication Number Publication Date
MA54379A MA54379A (fr) 2021-10-13
MA54379B1 true MA54379B1 (fr) 2023-12-29

Family

ID=64665802

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54379A MA54379B1 (fr) 2018-12-06 2019-12-05 Nouvelles formes cristallines d'un thienopyrimidine inhibiteur de mcl-1

Country Status (26)

Country Link
US (2) US12129261B2 (https=)
EP (1) EP3891156B1 (https=)
JP (1) JP7649241B2 (https=)
KR (1) KR102855345B1 (https=)
CN (1) CN113166169A (https=)
AR (1) AR117255A1 (https=)
AU (1) AU2019391329B2 (https=)
BR (1) BR112021010072A2 (https=)
CA (1) CA3121363A1 (https=)
DK (1) DK3891156T3 (https=)
EA (1) EA202191534A1 (https=)
ES (1) ES2971258T3 (https=)
FI (1) FI3891156T3 (https=)
HR (1) HRP20240211T1 (https=)
HU (1) HUE065266T2 (https=)
IL (1) IL283656B2 (https=)
LT (1) LT3891156T (https=)
MA (1) MA54379B1 (https=)
MD (1) MD3891156T2 (https=)
MX (1) MX2021006702A (https=)
PL (1) PL3891156T3 (https=)
PT (1) PT3891156T (https=)
RS (1) RS65047B1 (https=)
SI (1) SI3891156T1 (https=)
TW (1) TWI905090B (https=)
WO (1) WO2020115183A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO2020115183A1 (en) 2020-06-11
SI3891156T1 (sl) 2024-03-29
KR20210100148A (ko) 2021-08-13
EA202191534A1 (ru) 2021-10-27
KR102855345B1 (ko) 2025-09-03
FI3891156T3 (fi) 2024-02-07
PL3891156T3 (pl) 2024-05-13
TWI905090B (zh) 2025-11-21
HRP20240211T1 (hr) 2024-04-26
MA54379A (fr) 2021-10-13
BR112021010072A2 (pt) 2021-08-24
CN113166169A (zh) 2021-07-23
JP7649241B2 (ja) 2025-03-19
US20220017533A1 (en) 2022-01-20
EP3891156B1 (en) 2023-11-15
MD3891156T2 (ro) 2024-06-30
AU2019391329A1 (en) 2021-07-01
LT3891156T (lt) 2023-12-27
DK3891156T3 (da) 2024-02-19
EP3891156A1 (en) 2021-10-13
IL283656B1 (en) 2025-06-01
TW202039511A (zh) 2020-11-01
IL283656B2 (en) 2025-10-01
ES2971258T3 (es) 2024-06-04
IL283656A (en) 2021-07-29
CA3121363A1 (en) 2020-06-11
JP2022511495A (ja) 2022-01-31
MX2021006702A (es) 2021-07-07
HUE065266T2 (hu) 2024-05-28
NZ776907A (en) 2025-05-02
AU2019391329B2 (en) 2024-09-26
US20250011337A1 (en) 2025-01-09
RS65047B1 (sr) 2024-02-29
US12129261B2 (en) 2024-10-29
AR117255A1 (es) 2021-07-21
PT3891156T (pt) 2024-01-16

Similar Documents

Publication Publication Date Title
PH12021550310A1 (en) Novel sulfonamideurea compounds
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
SA521422143B1 (ar) 15-pgdh مثبط
MA29460B1 (fr) Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
EA200601661A1 (ru) δd-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
EA200600321A1 (ru) βd-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
EA200601662A1 (ru) δ-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
NO20061793L (no) 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
MA33240B1 (fr) Inhibiteurs de bêta-sécrétase
EA200600322A1 (ru) β-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
TW200716163A (en) A therapeutic agent for aβ related disorders
JO2793B1 (en) New Crystaline form V of Agomelatine, A process for It's Preparation and Pharmaceutical Compositions Containig it.
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l'humeur
MA54386B1 (fr) Modulateurs de trex1
MA54379B1 (fr) Nouvelles formes cristallines d'un thienopyrimidine inhibiteur de mcl-1
JOP20210157B1 (ar) تخليق 3-ميثيل-1، 2، 4-ثياديازول-5-كربوهيدرازيد أو ميثيل-d3 مُعَالَج بالديوتيريوم منه
WO2013152277A3 (en) Moenomycin analogs, methods of synthesis, and uses thereof
MX2009004343A (es) Compuestos organicos.
UA96568C2 (en) Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor